NL1008139C2 - Antimicrobiële peptiden. - Google Patents
Antimicrobiële peptiden. Download PDFInfo
- Publication number
- NL1008139C2 NL1008139C2 NL1008139A NL1008139A NL1008139C2 NL 1008139 C2 NL1008139 C2 NL 1008139C2 NL 1008139 A NL1008139 A NL 1008139A NL 1008139 A NL1008139 A NL 1008139A NL 1008139 C2 NL1008139 C2 NL 1008139C2
- Authority
- NL
- Netherlands
- Prior art keywords
- amino acids
- peptide
- peptides according
- domain
- amino acid
- Prior art date
Links
- 102000044503 Antimicrobial Peptides Human genes 0.000 title description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 171
- 150000001413 amino acids Chemical class 0.000 claims abstract description 99
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 77
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 7
- 229940024606 amino acid Drugs 0.000 claims description 80
- 235000001014 amino acid Nutrition 0.000 claims description 80
- 150000001408 amides Chemical class 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000003429 antifungal agent Substances 0.000 claims description 7
- 206010017533 Fungal infection Diseases 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 241000222122 Candida albicans Species 0.000 description 9
- 101000898505 Homo sapiens Histatin-3 Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- KSXBMTJGDUPBBN-VPKNIDFUSA-N histatin 5 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C1=CN=CN1 KSXBMTJGDUPBBN-VPKNIDFUSA-N 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 102400000777 His3-(20-43)-peptide Human genes 0.000 description 8
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940095731 candida albicans Drugs 0.000 description 6
- 229960003260 chlorhexidine Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 241000194019 Streptococcus mutans Species 0.000 description 5
- 241000194023 Streptococcus sanguinis Species 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- -1 m-maleimidobenzoyl Chemical group 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000008057 potassium phosphate buffer Substances 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 241000194024 Streptococcus salivarius Species 0.000 description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 3
- 241000222126 [Candida] glabrata Species 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 241000186046 Actinomyces Species 0.000 description 2
- 241000186045 Actinomyces naeslundii Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000222173 Candida parapsilosis Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 108010019494 Histatins Proteins 0.000 description 2
- 102000006492 Histatins Human genes 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 101800004819 PGLa Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241001148135 Veillonella parvula Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000009343 monoculture Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
- VYMHBQQZUYHXSS-UHFFFAOYSA-N 2-(3h-dithiol-3-yl)pyridine Chemical compound C1=CSSC1C1=CC=CC=N1 VYMHBQQZUYHXSS-UHFFFAOYSA-N 0.000 description 1
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 1
- OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FORGMRSGVSYZQR-YFKPBYRVSA-N L-leucinamide Chemical compound CC(C)C[C@H](N)C(N)=O FORGMRSGVSYZQR-YFKPBYRVSA-N 0.000 description 1
- 102000003752 Lipocalin 1 Human genes 0.000 description 1
- 108010057281 Lipocalin 1 Proteins 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 240000000968 Parkia biglobosa Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102000018968 Salivary Cystatins Human genes 0.000 description 1
- 108010026774 Salivary Cystatins Proteins 0.000 description 1
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 1
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 238000011482 antibacterial activity assay Methods 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL1008139A NL1008139C2 (nl) | 1998-01-27 | 1998-01-27 | Antimicrobiële peptiden. |
| CA002319094A CA2319094C (en) | 1998-01-27 | 1999-01-26 | Antimicrobial peptides |
| JP2000528598A JP2003524578A (ja) | 1998-01-27 | 1999-01-26 | 抗微生物性ペプチド |
| AT99902926T ATE278710T1 (de) | 1998-01-27 | 1999-01-26 | Antimikrobiell wirksame peptide |
| PCT/NL1999/000045 WO1999037678A2 (en) | 1998-01-27 | 1999-01-26 | Antimicrobial peptides |
| US09/601,124 US6638531B1 (en) | 1998-01-27 | 1999-01-26 | Antimicrobial peptides |
| EP99902926A EP1051433B1 (de) | 1998-01-27 | 1999-01-26 | Antimikrobiell wirksame peptide |
| AU23014/99A AU759026B2 (en) | 1998-01-27 | 1999-01-26 | Antimicrobial peptides |
| ES99902926T ES2229669T3 (es) | 1998-01-27 | 1999-01-26 | Peptidos antimicrobianos. |
| DE69920877T DE69920877T2 (de) | 1998-01-27 | 1999-01-26 | Antimikrobiell wirksame peptide |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL1008139 | 1998-01-27 | ||
| NL1008139A NL1008139C2 (nl) | 1998-01-27 | 1998-01-27 | Antimicrobiële peptiden. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL1008139C2 true NL1008139C2 (nl) | 1999-07-28 |
Family
ID=19766423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL1008139A NL1008139C2 (nl) | 1998-01-27 | 1998-01-27 | Antimicrobiële peptiden. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6638531B1 (de) |
| EP (1) | EP1051433B1 (de) |
| JP (1) | JP2003524578A (de) |
| AT (1) | ATE278710T1 (de) |
| AU (1) | AU759026B2 (de) |
| CA (1) | CA2319094C (de) |
| DE (1) | DE69920877T2 (de) |
| ES (1) | ES2229669T3 (de) |
| NL (1) | NL1008139C2 (de) |
| WO (1) | WO1999037678A2 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000001427A1 (en) * | 1998-07-02 | 2000-01-13 | Stichting Skeletal Tissue Engineering Group Amsterdam | Bone cement with antimicrobial peptides |
| NL1010692C2 (nl) * | 1998-12-01 | 2000-06-06 | Stichting Tech Wetenschapp | Antivirale peptiden. |
| EP1174027A1 (de) * | 2000-07-17 | 2002-01-23 | HOM Consultancy B.V. | Verwendungen antimikrobieller Peptide |
| US7550558B2 (en) * | 2001-06-01 | 2009-06-23 | Fundacao De Ampara A Pesquiso Do Estado De Sao Paolo (Fapesp) | Antimicrobial peptides and methods for identifying and using such peptides |
| US7550430B2 (en) * | 2003-08-18 | 2009-06-23 | E.I. Du Pont De Nemours And Company | Cationic antimicrobial peptides and compositions |
| JP2005350424A (ja) * | 2004-06-14 | 2005-12-22 | Kyocera Chemical Corp | 固形製剤および固形製剤の製造方法 |
| EP3384938A1 (de) | 2011-09-12 | 2018-10-10 | Moderna Therapeutics, Inc. | Manipulierte nukleinsäuren und verfahren zur verwendung davon |
| AU2013243949A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| EP2833923A4 (de) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | Modifizierte polynukleotide zur herstellung von proteinen |
| US8963676B1 (en) * | 2013-03-12 | 2015-02-24 | XP Power Limited | Configurable transformer module |
| WO2014144004A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The University Of Arkansas | Peptides with antifungal activity and methods of using the peptides |
| EP3423477B1 (de) | 2015-06-30 | 2021-09-29 | Chain Antimicrobials OY | Neue antimikrobielle peptide, deren varianten und verwendungen |
| WO2017001732A1 (en) | 2015-06-30 | 2017-01-05 | Oulun Yliopisto | New antimicrobial peptides, their variants and uses |
| ES2808780T3 (es) | 2015-06-30 | 2021-03-01 | Chain Antimicrobials Oy | Nuevos péptidos antimicrobianos, sus variantes y usos |
| KR20180101341A (ko) | 2015-11-10 | 2018-09-12 | 비스테라, 인크. | 리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도 |
| JP6658265B2 (ja) * | 2016-04-26 | 2020-03-04 | ライオン株式会社 | インビトロバイオフィルムモデルの製造方法、ならびに評価方法及び口腔用組成物を選定する方法 |
| EP3571223B1 (de) | 2017-01-18 | 2024-09-18 | Visterra, Inc. | Antikörpermolekularzneimittelkonjugate und verwendungen davon |
| EP3737750B1 (de) | 2018-01-09 | 2024-06-05 | Theriva Biologics, Inc. | Alkalische phosphatasemittel zur behandlung von entwicklungsstörungen des nervensystems |
| EP3768302A4 (de) | 2018-03-20 | 2021-12-15 | Synthetic Biologics, Inc. | Intestinale alkalische phosphataseformulierungen |
| EP3773686B1 (de) | 2018-03-20 | 2023-06-07 | Theriva Biologics, Inc. | Alkalische phosphatasemittel zur behandlung von bestrahlungsstörungen |
| JP2023521319A (ja) | 2020-04-03 | 2023-05-24 | ビステラ， インコーポレイテッド | 抗体分子－薬物コンジュゲートおよびその使用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991012815A1 (en) * | 1990-02-23 | 1991-09-05 | Bristol-Myers Squibb Company | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS CAUSED BY ORGANISMS SENSITIVE TO β-LACTAM ANTIBIOTICS |
| WO1992001462A1 (en) * | 1990-07-19 | 1992-02-06 | The Scripps Research Institute | Amphiphilic peptide compositions and analogues thereof |
| WO1993024138A1 (en) * | 1992-06-01 | 1993-12-09 | Magainin Pharmaceuticals, Inc. | Biologically active peptides having n-terminal substitutions |
| WO1996008270A2 (en) * | 1994-09-13 | 1996-03-21 | Magainin Pharmaceuticals Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
| WO1996040251A1 (en) * | 1995-06-07 | 1996-12-19 | Ophidian Pharmaceuticals, Inc. | Prevention and treatment of sepsis |
-
1998
- 1998-01-27 NL NL1008139A patent/NL1008139C2/nl not_active IP Right Cessation
-
1999
- 1999-01-26 AU AU23014/99A patent/AU759026B2/en not_active Ceased
- 1999-01-26 CA CA002319094A patent/CA2319094C/en not_active Expired - Fee Related
- 1999-01-26 DE DE69920877T patent/DE69920877T2/de not_active Expired - Fee Related
- 1999-01-26 WO PCT/NL1999/000045 patent/WO1999037678A2/en active IP Right Grant
- 1999-01-26 US US09/601,124 patent/US6638531B1/en not_active Expired - Fee Related
- 1999-01-26 AT AT99902926T patent/ATE278710T1/de not_active IP Right Cessation
- 1999-01-26 ES ES99902926T patent/ES2229669T3/es not_active Expired - Lifetime
- 1999-01-26 JP JP2000528598A patent/JP2003524578A/ja active Pending
- 1999-01-26 EP EP99902926A patent/EP1051433B1/de not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991012815A1 (en) * | 1990-02-23 | 1991-09-05 | Bristol-Myers Squibb Company | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS CAUSED BY ORGANISMS SENSITIVE TO β-LACTAM ANTIBIOTICS |
| WO1992001462A1 (en) * | 1990-07-19 | 1992-02-06 | The Scripps Research Institute | Amphiphilic peptide compositions and analogues thereof |
| WO1993024138A1 (en) * | 1992-06-01 | 1993-12-09 | Magainin Pharmaceuticals, Inc. | Biologically active peptides having n-terminal substitutions |
| WO1996008270A2 (en) * | 1994-09-13 | 1996-03-21 | Magainin Pharmaceuticals Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
| WO1996040251A1 (en) * | 1995-06-07 | 1996-12-19 | Ophidian Pharmaceuticals, Inc. | Prevention and treatment of sepsis |
Non-Patent Citations (8)
| Title |
|---|
| AOYAGI H ET AL: "SYNTHESIS OF ANTIBACTERIAL PEPTIDES, GRAMICIDIN S ANALOGS AND DESIGNED AMPHIPHILIC OLIGOPEPTIDES", TETRAHEDRON, vol. 44, no. 3, 1 January 1988 (1988-01-01), pages 877 - 886, XP000574054 * |
| CHEMICAL ABSTRACTS, vol. 103, no. 19, 11 November 1985, Columbus, Ohio, US; abstract no. 160837, SASAKI, TOORU ET AL: "Syntheses and properties of H-[Orn-Leu]n-OH (n = 1-12) and cyclo[Orn-Leu-]n (n = 2-8)" XP002083173 * |
| CHEMICAL ABSTRACTS, vol. 106, no. 25, 22 June 1987, Columbus, Ohio, US; abstract no. 214352, MIHARA, HISAKAZU ET AL: "Design and synthesis of basic amphiphilic peptides possessing antimicrobial activity and their interaction with lipids" XP002083172 * |
| MIHARA, HISAKAZU ET AL: "Design and synthesis of amphiphilic basic peptides with antibacterial activity and their interaction with model membrane", BULL. CHEM. SOC. JPN. (1987), 60(2), 697-706 CODEN: BCSJA8;ISSN: 0009-2673, 1987, XP002083171 * |
| PEPT. CHEM. (1985), VOLUME DATE 1984, 22ND, 361-6 CODEN: PECHDP;ISSN: 0388-3698, 1985 * |
| PEPT. CHEM. (1986), VOLUME DATE 1985, 23RD, 223-8 CODEN: PECHDP;ISSN: 0388-3698, 1986 * |
| TAKAHASHI, SHO ET AL: "Synthesis of.alpha.-helices having a positively charged random coil-block on either N- or C-terminal", BULL. CHEM. SOC. JPN. (1988), 61(7), 2467-71 CODEN: BCSJA8;ISSN: 0009-2673, 1988, XP002083167 * |
| TOSSI, ALESSANDRO ET AL: "Identification and characterization of a primary antibacterial domain in CAP18, a lipopolysaccharide binding protein from rabbit leukocytes", FEBS LETT. (1994), 339(1-2), 108-12 CODEN: FEBLAL;ISSN: 0014-5793, 1994, XP002083170 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2229669T3 (es) | 2005-04-16 |
| EP1051433B1 (de) | 2004-10-06 |
| AU2301499A (en) | 1999-08-09 |
| WO1999037678A3 (en) | 1999-10-14 |
| ATE278710T1 (de) | 2004-10-15 |
| CA2319094C (en) | 2009-03-17 |
| AU759026B2 (en) | 2003-04-03 |
| EP1051433A2 (de) | 2000-11-15 |
| JP2003524578A (ja) | 2003-08-19 |
| US6638531B1 (en) | 2003-10-28 |
| DE69920877D1 (de) | 2004-11-11 |
| WO1999037678A2 (en) | 1999-07-29 |
| CA2319094A1 (en) | 1999-07-29 |
| DE69920877T2 (de) | 2005-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL1008139C2 (nl) | Antimicrobiële peptiden. | |
| US9351490B2 (en) | Selectively targeted antimicrobial peptides and the use thereof | |
| US7723468B2 (en) | Antimicrobial peptide, compositions, and uses therefor | |
| DE102007036128A1 (de) | Antibiotische Peptide | |
| US10174081B2 (en) | Antimicrobial peptides and uses therefore | |
| KR101896927B1 (ko) | 흰점박이꽃무지에서 유래한 항균 펩타이드 프로테티아마이신 1 및 그의 조성물 | |
| Zhang et al. | Pleurocidin congeners demonstrate activity against Streptococcus and low toxicity on gingival fibroblasts | |
| JP2003524578A5 (de) | ||
| US5885965A (en) | Anti-fungal D-amino acid histatin-based peptides | |
| EP2750689B1 (de) | Modifizierte apidaecinderivate als antibiotische peptide | |
| KR20180052181A (ko) | 흰점박이꽃무지에서 유래한 항균 펩타이드 프로테티아마이신 2 및 그의 조성물 | |
| KR101953834B1 (ko) | 왕귀뚜라미에서 유래한 항균 펩타이드 테레오그릴루신 2 및 그의 조성물 | |
| US7348402B2 (en) | Antimicrobial peptide, its analogs and antimicrobial composition comprising them | |
| US10150795B2 (en) | Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same | |
| CA2491011A1 (fr) | Peptides lineaires cationiques ayant des proprietes antibacteriennes et/ou antifongiques | |
| US5969098A (en) | Yeast-toxin-related protein for antimicrobial vaccine and sterilizing preservative use | |
| JP3488133B2 (ja) | 抗菌性ペプチド | |
| IT202100029738A1 (it) | Peptide ad attività antimicotica e antibatterica | |
| US20090149391A1 (en) | Novel antimicrobial bolisin peptides | |
| WO2013064633A1 (de) | Oncopeltus-peptidderivate als antimikrobielle peptide | |
| SE2151338A1 (en) | Truncated peptides | |
| DE10160170A1 (de) | Neue antimikrobielle Bolisinpeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SD | Assignments of patents |
Owner name: AM-PHARMA B.V. |
|
| VD1 | Lapsed due to non-payment of the annual fee |
Effective date: 20040801 |